Detailed answers about C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED, including incorporation, status, business activity, and accounts information.
When was C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED founded?
C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED was officially incorporated on 9 January 2024 and is registered under company number 15401074. Incorporation establishes the company as a legal entity registered at Companies House, allowing it to trade, enter contracts, and operate under UK company law.
What type of company is C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED?
Private Limited Company. This classification indicates the legal structure of the company, which determines the way it is governed, its liability, and regulatory obligations. A private limited company (Ltd) limits the personal liability of its shareholders.
What is the current status of C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED?
C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED's current status is Active. The company status indicates whether it is actively trading, dormant, or has been dissolved. Maintaining an active status is essential for legally conducting business, filing accounts, and maintaining credibility with partners and lenders.
What does C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED do?
C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED operates in the following sectors: 72110 - Research and experimental development on biotechnology, 74909 - Other professional, scientific and technical activities n.e.c.. These SIC codes provide insight into the company's business activities and industry focus.
What is C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED's registered address?
The registered office address of C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED is 20 MANNIN WAY, LANCASTER, ENGLAND, LA1 3SW. This is the official address filed with Companies House for legal and statutory correspondence.
Is C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED financially stable?
The most recent accounts for C3 BIOTECHNOLOGIES (HYPERSONICS) LIMITED were made up to 30 September 2024, filed as DORMANT. Next accounts are due by 30 June 2026.